119 related articles for article (PubMed ID: 9191872)
1. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
4. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.
Cesano A; Visonneau S; Tran T; Santoli D
Int J Oncol; 1999 Feb; 14(2):245-51. PubMed ID: 9917498
[TBL] [Abstract][Full Text] [Related]
6. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
9. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
Cesano A; Visonneau S; Santoli D
Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
[TBL] [Abstract][Full Text] [Related]
10. Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Jeglum KA; Santoli D
Oncol Rep; 1999; 6(6):1181-8. PubMed ID: 10523677
[TBL] [Abstract][Full Text] [Related]
11. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
Visonneau S; Cesano A; Torosian MH; Santoli D
Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
[TBL] [Abstract][Full Text] [Related]
12. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
[TBL] [Abstract][Full Text] [Related]
15. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.
Cesano A; Visonneau S; Cioé L; Clark SC; Rovera G; Santoli D
J Clin Invest; 1994 Sep; 94(3):1076-84. PubMed ID: 8083348
[TBL] [Abstract][Full Text] [Related]
16. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a karyotypically normal cytotoxic leukemic T-cell line from a T-ALL sample engrafted in SCID mice.
Cesano A; O'Connor R; Nowell PC; Lange B; Clark SC; Santoli D
Blood; 1993 May; 81(10):2714-22. PubMed ID: 8490180
[TBL] [Abstract][Full Text] [Related]
18. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
19. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
Cesano A; Visonneau S; Rovera G; Santoli D
Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
